| Detailed Table Item | HTML Link |
|---|---|
| Detailed Tables | HTML |
| Introduction | HTML |
| Reference Tools | HTML |
| Appendix A: Glossary | HTML |
| Appendix B: List of Tables | HTML |
| Acknowledgments | HTML |
| Note: The Reference Tools section provides guidance in navigating the 2024 Detailed Tables. Appendix A contains definitions of measures and terms. In this table of contents, NSDUH = National Survey on Drug Use and Health; and SE = standard errors and p values for tests of differences of percentages. In the table below, outcome measures are listed as rows and various common domains are listed as columns. Tables presented by other domains (e.g., tables presented only for the 12+ age group by level of mental illness) are listed in the “Other” column. When a table covers multiple domains, the table will be listed in a single column corresponding to the most prominent domain out of those listed in the table below. | |
| Detailed Table Section | Detailed Age | Standard Age | Demographic Characteristics | Geographic/ Socioeconomic Characteristics | College Enrollment | Other | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Section 1: Illicit Drug Use/Misuse Tables | ||||||||||||
| Illicit drug use/misuse | 1.6 to 1.21 | (SE) | 1.1 to 1.5 | (SE) | 1.23 to 1.69 | (SE) | 1.70 to 1.107 | (SE) | ||||
| Any use/misuse of prescription psychotherapeutics | 1.22 | (SE) | ||||||||||
| Specific hallucinogen use, inhalant use, needle use, and heroin use | 1.108 and 1.109 | (SE) | ||||||||||
| Any use/misuse of prescription opioid subtypes | 1.110 to 1.114 | (SE) | ||||||||||
| Any use/misuse of prescription stimulant subtypes | 1.115 to 1.119 | (SE) | ||||||||||
| Any use/misuse of prescription tranquilizer subtypes | 1.120 to 1.124 | (SE) | ||||||||||
| Any use/misuse of prescription sedative subtypes | 1.125 to 1.129 | (SE) | ||||||||||
| Any use/misuse of prescription benzodiazepine subtypes | 1.130 to 1.134 | (SE) | ||||||||||
| Section 2: Tobacco Product Use, Nicotine Vaping, and Alcohol Use Tables | ||||||||||||
| Tobacco product use or nicotine vaping, tobacco product use, nicotine vaping, and alcohol use | 2.2 to 2.9 | (SE) | 2.1 | (SE) | 2.10 to 2.29 | (SE) | 2.30 to 2.43 | (SE) | ||||
| Alcohol use, binge alcohol use, and heavy alcohol use | 2.44 to 2.45 | (SE) | 2.46 to 2.47 | (SE) | ||||||||
| Section 3: Risk and Protective Factor Tables | ||||||||||||
| Perceived risk and availability of substances | 3.1 | (SE) | 3.2 to 3.5 | (SE) | ||||||||
| Risk and protective factors | 3.6 to 3.15 | (SE) | ||||||||||
| Section 4: Incidence Tables | ||||||||||||
| Initiation of substance use/misuse, tobacco product use, nicotine vaping, and alcohol use | 4.5 to 4.9 | (SE) | 4.1 to 4.4 | (SE) | 4.10 | (SE) | ||||||
| Mean age at first substance use/misuse, tobacco product use, nicotine vaping, and alcohol use | 4.11 | (SE) | ||||||||||
| Section 5: Substance Use Disorder and Treatment Tables | ||||||||||||
| Substance use disorder (SUD) | 5.3 | (SE) | 5.1 | (SE) | 5.4 to 5.10 | (SE) | 5.11 to 5.13 | (SE) | ||||
| SUD severity level | 5.2 | (SE) | ||||||||||
| Substance use treatment | 5.19 and 5.20 | (SE) | ||||||||||
| 5.14 | (SE) | 5.28 to 5.31 | (SE) | 5.15 to 5.17 | (SE) | 5.18 | (SE) | |||||
| Medications for alcohol or opioid use disorder | 5.21 to 5.22 | (SE) | 5.23 to 5.24 | (SE) | ||||||||
| Received substance use treatment through telehealth | 5.25 | (SE) | 5.26 | (SE) | ||||||||
| Types and locations of substance use treatment and other services | 5.27 | (SE) | ||||||||||
| Classified as needing and receipt of substance use treatment | 5.32 to 5.33 | (SE) | ||||||||||
| Perceived unmet need for substance use treatment | 5.34 to 5.35 | (SE) | ||||||||||
| Detailed reasons for not receiving substance use treatment | 5.36 | (SE) | ||||||||||
| Section 6: Adult Mental Health Tables | ||||||||||||
| Mental illness | 6.2 | (SE) | ||||||||||
| 6.5 | (SE) | 6.3 | (SE) | |||||||||
| 6.1 | (SE) | 6.7 | (SE) | 6.6 | (SE) | |||||||
| 6.4 | (SE) | 6.18 and 6.19 | (SE) | 6.8 | (SE) | 6.83 to 6.85 | (SE) | 6.48 | (SE) | |||
| SUD and mental illness | 6.9 and 6.10 | (SE) | 6.11 | (SE) | ||||||||
| 6.12 and 6.13 | (SE) | 6.14 | (SE) | |||||||||
| 6.15 | (SE) | 6.16 | (SE) | |||||||||
| SUD severity level | 6.17 | (SE) | ||||||||||
| Types and locations of mental health treatment and other services | 6.20 | (SE) | ||||||||||
| Mental health treatment | 6.21 | (SE) | ||||||||||
| 6.23 to 6.26 | (SE) | 6.27 | (SE) | |||||||||
| 6.43 to 6.47 | (SE) | 6.22 | (SE) | 6.83 to 6.85 | (SE) | 6.87 | (SE) | |||||
| Substance use treatment | 6.27 | (SE) | ||||||||||
| 6.87 | (SE) | |||||||||||
| Perceived unmet need for mental health treatment | 6.28 | (SE) | 6.29 | (SE) | ||||||||
| 6.30 | (SE) | 6.31 | (SE) | |||||||||
| 6.32 | (SE) | 6.33 | (SE) | 6.87 | (SE) | |||||||
| Detailed reasons for not receiving mental health treatment | 6.34 to 6.36 | (SE) | ||||||||||
| Severity of symptoms of generalized anxiety disorder (GAD) | 6.37 | (SE) | 6.38 | (SE) | ||||||||
| Major depressive episode (MDE) | 6.49 | (SE) | ||||||||||
| 6.39 to 6.40 | (SE) | 6.41 | (SE) | 6.42 | (SE) | 6.83 to 6.85 | (SE) | 6.87 | (SE) | |||
| Substance use/misuse, tobacco product use or nicotine vaping, and alcohol use | 6.50 to 6.59 | (SE) | 6.78 | (SE) | ||||||||
| SUD | 6.80 | (SE) | ||||||||||
| 6.60 to 6.69 | (SE) | 6.87 | (SE) | |||||||||
| Suicidality | 6.71 to 6.73 | (SE) | 6.77 | (SE) | ||||||||
| 6.75 and 6.76 | (SE) | 6.79 | (SE) | |||||||||
| 6.70 | (SE) | 6.81 and 6.82 | (SE) | 6.74 | (SE) | 6.83 to 6.85 | (SE) | 6.86 | (SE) | |||
| Serious psychological distress (SPD) | 6.88 and 6.89 | (SE) | 6.87 | (SE) | ||||||||
| Section 7: Youth Mental Health Tables | ||||||||||||
| Severity of symptoms of GAD | 7.1 | (SE) | 7.2 | (SE) | ||||||||
| MDE | 7.3 | (SE) | ||||||||||
| 7.28 and 7.29 | (SE) | 7.4 | (SE) | |||||||||
| Types and locations of mental health treatment and other services | 7.5 | (SE) | ||||||||||
| Mental health treatment | 7.6 | (SE) | 7.7 | (SE) | ||||||||
| 7.8 | (SE) | 7.9 | (SE) | |||||||||
| 7.10 | (SE) | 7.11 | (SE) | |||||||||
| 7.12 | (SE) | 7.13 | (SE) | |||||||||
| 7.14 | (SE) | 7.15 | (SE) | |||||||||
| 7.34 | (SE) | 7.16 | (SE) | 7.17 | (SE) | |||||||
| Perceived unmet need for mental health treatment | 7.18 | (SE) | 7.19 | (SE) | ||||||||
| 7.20 | (SE) | 7.21 | (SE) | |||||||||
| 7.22 | (SE) | 7.23 | (SE) | |||||||||
| Detailed reasons for not receiving mental health treatment | 7.24 to 7.26 | (SE) | ||||||||||
| Substance use/misuse, tobacco product use or nicotine vaping, and alcohol use | 7.27 | (SE) | ||||||||||
| SUD | 7.30 | (SE) | ||||||||||
| SUD and MDE | 7.31 | (SE) | 7.32 | (SE) | ||||||||
| SUD severity level | 7.33 | (SE) | ||||||||||
| Substance use treatment | 7.34 | (SE) | ||||||||||
| Suicidality | 7.35 to 7.38 | (SE) | ||||||||||
| 7.42 | (SE) | 7.39 to 7.41 | (SE) | |||||||||
| Section 8: Miscellaneous Tables | ||||||||||||
| Drugs used with alcohol or within 2 hours of alcohol use | 8.1 | (SE) | ||||||||||
| Cigarette use and nicotine dependence | 8.2 | (SE) | 8.3 | (SE) | 8.4 | (SE) | ||||||
| Source for most recently misused prescription pain relievers, prescription stimulants, prescription tranquilizers, and prescription sedatives | 8.5 to 8.12 | (SE) | ||||||||||
| Main reasons for last episode of prescription psychotherapeutic misuse | 8.13 to 8.14 | (SE) | ||||||||||
| Social context, location, and source of most recent alcohol use | 8.15 to 8.16 | (SE) | ||||||||||
| Illicit drug, illegally made fentanyl, and other substance use | 8.17 to 8.19 | (SE) | ||||||||||
| Modes of marijuana use | 8.20 | (SE) | 8.21 | (SE) | ||||||||
| Substance use/misuse, tobacco product use or nicotine vaping, and alcohol use | 8.23 to 8.25 | (SE) | 8.22 | (SE) | ||||||||
| 8.34 to 8.36 | (SE) | 8.26 | (SE) | 8.32 and 8.33 | (SE) | |||||||
| SUD | 8.27 to 8.29 | (SE) | ||||||||||
| Drove under the influence of alcohol, marijuana, select illicit drugs, select illicit drugs other than marijuana, and alcohol or select illicit drugs | 8.30 | (SE) | 8.31 | (SE) | ||||||||
| Perceived ever having had a substance use problem or mental health issue and perceived recovery | 8.37 to 8.39 | (SE) | ||||||||||
| Section 9: Trend Tables | ||||||||||||
| Substance use/misuse, tobacco product use, and alcohol use | 9.1 to 9.15 | (SE) | 9.16 to 9.17 | (SE) | ||||||||
| 9.52 to 9.61 | (SE) | 9.73 and 9.74 | (SE) | |||||||||
| Frequency of substance use | 9.20 to 9.33 | (SE) | 9.18 and 9.19 | (SE) | ||||||||
| Initiation of substance use | 9.34 to 9.38 | (SE) | ||||||||||
| Mean age of first substance use | 9.39 | (SE) | ||||||||||
| SUD | 9.40 to 9.44 | (SE) | ||||||||||
| Mental illness | 9.45 and 9.46 | (SE) | 9.47 and 9.48 | (SE) | 9.49 and 9.50 | (SE) | ||||||
| Co-occurring SUD and mental illness | 9.51 | (SE) | ||||||||||
| Suicidality | 9.65 to 9.67 | (SE) | 9.68 to 9.70 | (SE) | ||||||||
| 9.62 to 9.64 | (SE) | 9.78 to 9.80 | (SE) | 9.81 to 9.83 | (SE) | |||||||
| MDE | 9.71 to 9.72 | (SE) | 9.75 to 9.76 | (SE) | ||||||||
| Co-occurring SUD and MDE | 9.77 | (SE) | ||||||||||
| Section 10: Sample Size and Population Tables | ||||||||||||
| Sample size and population | 10.2 and 10.3 | (SE) | ||||||||||
| 10.6 | (SE) | |||||||||||
| 10.1 | (SE) | 10.8 | (SE) | 10.4 to 10.5 | (SE) | 10.7 | (SE) | |||||
